Ocugen, Inc. (NASDAQ:OCGN – Get Free Report) CFO Treerita Essali Johnson-Greene bought 21,000 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was bought at an average cost of $1.23 per share, with a total value of $25,830.00. Following the acquisition, the chief financial officer directly owned 521,000 shares of the company’s stock, valued at approximately $640,830. The trade was a 4.20% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Ocugen Stock Up 4.2%
OCGN stock opened at $1.23 on Thursday. The stock has a market capitalization of $416.38 million, a P/E ratio of -5.13 and a beta of 2.19. The company has a current ratio of 1.86, a quick ratio of 1.86 and a debt-to-equity ratio of 4.17. Ocugen, Inc. has a 12 month low of $0.90 and a 12 month high of $2.73. The firm has a 50-day moving average price of $1.50 and a 200-day moving average price of $1.58.
Ocugen (NASDAQ:OCGN – Get Free Report) last posted its earnings results on Tuesday, May 5th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). The company had revenue of $1.53 million during the quarter, compared to the consensus estimate of $0.42 million. Ocugen had a negative return on equity of 127,987.80% and a negative net margin of 1,192.18%. As a group, equities research analysts anticipate that Ocugen, Inc. will post -0.22 EPS for the current fiscal year.
Analyst Ratings Changes
Get Our Latest Analysis on Ocugen
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the business. UBS Group AG increased its position in Ocugen by 373.2% during the 4th quarter. UBS Group AG now owns 4,849,353 shares of the company’s stock valued at $6,547,000 after purchasing an additional 3,824,474 shares during the period. State Street Corp increased its position in Ocugen by 193.6% during the 4th quarter. State Street Corp now owns 3,978,738 shares of the company’s stock valued at $5,371,000 after purchasing an additional 2,623,361 shares during the period. Marshall Wace LLP acquired a new stake in Ocugen during the 4th quarter valued at approximately $3,417,000. Goldman Sachs Group Inc. increased its position in Ocugen by 2,256.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,302,475 shares of the company’s stock valued at $3,108,000 after purchasing an additional 2,204,765 shares during the period. Finally, Renaissance Technologies LLC increased its position in Ocugen by 485.9% during the 4th quarter. Renaissance Technologies LLC now owns 1,700,400 shares of the company’s stock valued at $2,296,000 after purchasing an additional 1,410,200 shares during the period. Institutional investors own 10.27% of the company’s stock.
Ocugen Company Profile
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.
In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.
Read More
- Five stocks we like better than Ocugen
- 2 Quantum Stocks Are Drawing Capital as AI Infrastructure Hits a Wall
- After an Initial Panic, Wall Street’s Leaning Into Apple’s New Siri AI
- Cheap Thrills: Why These 3 Entertainment Stocks Are Soaring
- CoreWeave Insider Sales Look Big, But Should Investors Worry?
Receive News & Ratings for Ocugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocugen and related companies with MarketBeat.com's FREE daily email newsletter.
